Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Alaunos Therapeutics clinical trials
Also known as Ziopharm.
The registry lists 37 studies whose lead sponsor is Alaunos Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Alaunos Therapeutics.
- Alaunos Therapeutics37 studiesSame company
Something wrong?
Focus areas
Conditions Alaunos Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 37 of 37.
- Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsCompletedNCT05292859
- HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid TumorsTerminatedNCT05124743
- Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue SarcomaTerminatedNCT01168791Phase 3
- Study of ZIO-201 in Advanced SarcomaCompletedNCT00439686Phase 1/2
- A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue SarcomaTerminatedNCT00718484Phase 2
- Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast CancerTerminatedNCT01113970Phase 1
- Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)TerminatedNCT01555710Phase 3
- Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow CancersTerminatedNCT00421213Phase 2
- A Phase-II Trial of ZIO 101 in Advanced Hepatocellular CarcinomaTerminatedNCT00423306Phase 2
- Phase I Study in Advanced Solid TumorsCompletedNCT00591292Phase 1
- Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid TumorsTerminatedNCT00726687Phase 1
- Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With MalignanciesCompletedNCT01242072Phase 1
- A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001bCompletedNCT00423644Phase 2
- Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and LymphomasCompletedNCT00592163Phase 1
- Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasCompletedNCT00591422Phase 1
- Study of Oral Palifosfamide Tris in Solid TumorsWithdrawnNCT00607711Phase 1
- Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid TumorsCompletedNCT00591383Phase 1
- Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid TumorsCompletedNCT01340547Phase 1
- Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsTerminatedNCT05194735Phase 1/2
- Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat MelanomaCompletedNCT01397708Phase 1/2
- Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.TerminatedNCT01703754Phase 2
- A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast CancerTerminatedNCT02423902Phase 1/2
- Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102CompletedNCT03679754Phase 1
- A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPGTerminatedNCT03330197Phase 1/2
- A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102CompletedNCT03636477Phase 1
- Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaTerminatedNCT04006119Phase 2
- A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant GliomaCompletedNCT02026271Phase 1
- Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV MelanomaCompletedNCT00815607Phase 1
- Study of Oral Darinaparsin in Patients With Advanced Solid TumorsCompletedNCT01139346Phase 1
- A Phase I Trial of ZIO-101 in Solid TumorsCompletedNCT00591396Phase 1
- A Phase I Trial of ZIO-101 in Hematologic CancersCompletedNCT00592046Phase 1
- Phase I Study of Indibulin in Patients With Solid TumorsCompletedNCT00591136Phase 1
- Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) ScansCompletedNCT00591890Phase 1
- Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat LymphomaWithdrawnNCT01139359Phase 1
- Study of ZIO-101 in Multiple MyelomaCompletedNCT00303199Phase 1/2
- A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced CancerCompletedNCT00421135Phase 1
- Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid TumorsCompletedNCT00608803Phase 1